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Abstract 
Objective: Simvastatin has been shown to enhance osseointegration of pure titanium 
implants in osteoporotic rats. This study aimed to evaluate the relationship between the serum 
level of bone formation markers and the osseointegration of pure titanium implants in 
osteoporotic rats treated with simvastatin. 
Materials and methods: Fifty-four female Sprague Dawley rats, aged 3 months old, were 
randomly divided into three groups: Sham-operated group (SHAM; n=18), ovariectomized 
group (OVX; n=18), and ovariectomized with Simvastatin treatment group (OVX+SIM; 
n=18). Fifty-six days after ovariectomy, screw-shaped titanium implants were inserted into 
the tibiae. Simvastatin was administered orally at 5mg/kg each day after the placement of the 
implant in the OVX+SIM group. The animals were sacrificed at either 28 or 84 days after 
implantation and the undecalcified tissue sections were processed for histological analysis. 
Total alkaline phosphatase (ALP), bone specific alkaline phosphatase (BALP) and bone Gla 
protein (BGP) were measured in all animal sera collected at the time of euthanasia and 
correlated with the histological assessment of osseointegration. 
Results: The level of ALP in the OVX group was higher than the SHAM group at day 28, 
with no differences between the three groups at day 84. The level of BALP in the OVX+SIM 
group was significantly higher than both OVX and SHAM groups at days 28 and 84. 
Compared with day 28, the BALP level of all three groups showed a significant decrease at 
day 84. There were no significant differences in BGP levels between the three groups at day 
28, but at day 84 the OVX+SIM group showed significantly higher levels than both the OVX 
and SHAM groups.  There was a significant increase in BGP levels between days 28 and 84 
in the OVX+SIM group. The serum bone marker levels correlated with the histological 
assessment showing reduced  osseointegration in the OVX compared to the SHAM group 
which is subsequently reversed in the OVX+SIM group. 
Conclusion:  The results from this study indicate that the serum level of bone formation 
markers, especially BALP and BGP, could be correlated with the degree of osseointegration 
around titanium implants in osteoporotic rats treated with simvastatin.  
 Medical conditions that affect bone quantity and quality may have a detrimental effect on 
osseointegration. Osteoporosis is a disease that has been reported to have negative effects on 
bone healing during dental implant osseointegration and is therefore considered a risk factor 
for implant failure (Motohashi et al. 1999, Yamazaki et al. 1999, Lugero et al. 2000, Pan et al. 
2000, Duarte et al. 2005).  Various therapeutic approaches have been proposed for the 
improvement of osseointegration of dental implants in patients with osteoporosis (Qi et al. 
2004, Maimoun et al. 2010, Dayer et al. 2010, Du et al. 2009, Viera-Negron et al. 2008). 
Currently, most drugs used for the treatment of osteoporosis predominantly work by 
suppressing bone resorption by slowing down bone turnover and subsequently reducing bone 
loss. Theoretically, drugs that could enhance bone formation would be more likely to improve 
the osseointegration of dental implants in low quality bone such as that found in osteoporotic 
patients.  
Simvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitor. It is widely used as a cholesterol-lowering drug and inhibits hepatic cholesterol 
biosynthesis. Recent studies have shown a beneficial effect of statins on bone mineral density 
(BMD) (Serin-Kilicoglu & Erdemli 2007, Uzzan et al. 2007). It has been suggested that 
several statin drugs, including simvastatin, increase the mRNA expression of bone 
morphogenetic protein (BMP-2) in osteoblasts, with a subsequent increase in bone formation 
when injected subcutaneously adjacent to murine calvaria (Mundy et al. 1999). Several 
animal and human studies have been performed to elucidate the clinical importance of statins. 
Most experimental and epidemiological studies have shown statins to have benefitial effects 
on bone metabolism, as evaluated by BMD (Uzzan et al. 2007, Chuengsamarn et al. 2010, 
Montagnani et al. 2003, Rejnmark et al. 2004) and fracture risk (Skoglund & Aspenberg 
2007, Pasco et al. 2002). Statins have therefore been proposed as potential agents in the 
treatment of osteoporosis. Previous studies also suggest that simvastatin can promote 
osteogenesis around titanium implants (Ayukawa 2004, Ayukawa et al. 2010, Basarir et al. 
2009).  
Molecules associated with bone formation and turnover as well as their by-products, have 
been widely utilized as markers of bone metabolism and hence have an established role in 
osteoporotic status assessment and the evaluation of treatment outcomes. Alkaline 
phosphatase (ALP), and in particular bone specific alkaline phosphatase (BALP), and bone 
gamma-carboxyglutamic acid-containing (also known as osteocalcin) protein (BGP), are all 
associated with osteoblast activity and the serum levels of these proteins has been used to 
assess bone formation. BALP is associated with early stages of osteogenesis and BGP is 
associated with subsequent bone mineralization (Biver et al. 2011, Pagani et al. 2005). 
In our previous report, simvastatin was shown to have a positive effect on the 
osseointegration of titanium in the tibias of osteoporetic rats (Du et al. 2009). However, the 
mechanism via which simvastatin influences osseointergration in ovariectomized (OVX) rats 
is unclear.  This study aims to address this issue by evaluating the relationship between the 
systemic level of bone formation biochemical markers and the osseointegration of implants in 
OVX rats treated with simvastatin. 
 
Materials and methods 
Experimental Design 
The study was conducted according to a protocol approved by the Animal Care and Use 
Committee of Fujian Medical University. The study protocol has been previously described 
(Du et al. 2009) and is summarized in Figure 1. Briefly, fifty-four 3-month-old female 
Sprague-Dawley rats (SLAC Laboratory AnimalCo. Ltd, Shanghai, China) were divided into 
three groups. Each group contained 18 rats by randomized block design: i.e. sham-operated 
(SHAM) ovariectomized (OVX) and ovariectomized with simvastatin treatment (OVX+SIM) 
groups. In the OVX and OVX+SIM groups, the ovaries were exposed and completely excised 
bilaterally using an abdominal approach. In the SHAM group, the ovaries were exposed and 
equal volume of fat tissue beside each ovary was excised. After surgery, the fascia and skin 
were closed and sutured. Commercial laboratory rat chow (Experimental Animal Centre of 
Zhejiang University, China) and water were available ad libitum. Osteoporotic changes due to 
ovariectomy were verified by sacrificing two rats from each group and recovering the 
proximal tibial metaphyses and uterine horns 56 days after ovariectomy as described 
previously (Du et al. 2009). 
Implant placement 
Fifty-six days after ovariectomy surgery, screw-shaped machined surface titanium 
implants (length=5mm, diameter=2mm, thread pitch =1mm, Jiuzhou Co., Xian, China) were 
inserted in the left tibia of each rat as previously described (Du et al. 2009).  Briefly, under 
general anesthesia attained by administration of 2.5% pentobarbital sodium (Chemical Agent 
Co., Shanghai,China) at 45mg/kg body weight, the surface of the proximal metaphyses of the 
tibia was exposed by an incision approximately 10mm in length. Under constant saline 
irrigation, bicortical implant beds were prepared with a dental bur (Zhongbang Co., Xian, 
China) at a rotary speed not exceeding 1500 rpm. The implants were then inserted until the 
screw threads were completely buried in bone (Fig. 1), after which the soft tissue was 
replaced and sutured. Simvastatin was administered orally at 5mg/kg per day after implant 
surgery to the OVX+SIM group. Saline was given as a placebo to the other two groups. Nine 
animals from each group were sacrificed either at 28 or 84 days after implantation (Fig 2). 
Histological assessment 
After sacrificing the rats, the left tibiae containing the titanium implants were harvested and 
fixed in 4% neutral formalin for 48 hours. The specimens were dehydrated in a series of 
graded alcohol and embedded in polyester resin without decalcification. Undecalcified 
sections approximately 30 µm thick and longitudinal to the implant, were cut with a Leitz 
1600 saw microtome (LeitzWetzlar GmbH, Wetzlar, Germany) and prepared using the bone-
grinding slice technique (Du et al. 2009). Three sections were obtained from each implant 
and stained with 0.1% toluidine blue (SigmaAldrich, St Louis, MO, USA) and methylene 
blue-basic fuchsin (Sigma-Aldrich, StLouis, MO, USA), and subsequently qualitatively 
analysed with light microscopy. The percentage of bone to-implant contact (BIC%) in the 
cancellous area was measured bilaterally as previously described (Du et al. 2009). 
Serum biochemical markers  
To examine the relationship between serum markers of bone formation and implant 
osseointegration in the three groups, serum was collected at the time of sacrifice. According 
to the protocols provided by the manufacturers, the amount of BGP (Adlitteram Diagnostic 
Laboratories, USA) and BALP (Adlitteram Diagnostic Laboratories, USA) in rat serum were 
measured using an enzyme-linked immunosorbent assay (ELISA). Total serum ALP was also 
analyzed using an automated analyzer (Sysmex, Chemix 180, Japan).  
Statistical methods 
Differences in serum bone marker levels between the three groups were assessed using a one-
way analysis of variance (ANOVA) followed by Fisher's LSD post hoc test (a=0.05). 
Statistical analyses were performed using the Sigma Statt statistics package (SPSS Inc., 
Chicago, IL, USA). 
 
 Results 
 
Histological analysis 
A histomorphometric quantitative comparison of osseointegration in the three treatment 
groups has been previously presented (Du et al. 2009). In this study, the focus is on a 
descriptive analysis of the histological features that are relevant to osteogenesis and bone 
remodeling for the purpose of correlation with the serum level of markers that are indicative 
of bone catabolic activity. Figures 3-5 show the histological characteristics of the bone 
healing 28 and 84 days following implant placement in the three groups.  
 
Day 28 
In the OVX group, there was less newly formed bone around the implants compared with the 
OVX+SIM and SHAM groups at day 28 following implantation (Figs 3a-c, 4a-c). There were 
fewer osteoblasts in the newly formed bone matrix surrounding the implant and the bone 
matrix around the implants was thin and discontinuous. Evidence of osteoclastic activity was 
noted in the newly formed bone in the OVX group (Fig. 5a). Furthermore, in the cancellous 
bone away from the implant surface there were fewer mineralized traberculae in the OVX 
group than in the SHAM and OVX+SIM groups.  At day 28, the newly formed bone adjacent 
to the implants in both the SHAM and OVX±SIM groups showed similar morphology (Fig. 
3a,c). Compared with the OVX group, both the OVX+SIM and SHAM groups exhibited 
more bone around the implants, both in terms of matrix thickness and continuity of 
mineralized tissue coverage of the implant surface (Figs 3a-c, 4a-c). In the OVX+SIM group, 
most of the newly formed bone matrix around the implants appeared to be less mature than 
the SHAM group at day 28 (Fig. 4c).  
 Day 84 
At 84 days after implantation, the histological results showed more newly formed bone 
covering the implant surface than at 28 days in all three groups (Figs 3d-f, 4d-f). The changes 
in both the SHAM and OVX+SIM groups were similar, with the newly formed bone on the 
implant surface becoming thicker over time (Figs 3d,f, 4d,f). In the OVX group, the amount 
of new bone covering the implant surface was thinner compared with the new bone around 
implants seen in the OVX+SIM and SHAM groups (Figs 3 and 4). In the OVX group, there 
was greater evidence of both osteoblastic and osteoclastic activity in the bone matrix 
surrounding the implants (Fig. 5b) compared to the other groups.  In the cancellous bone 
away from the implant surface, it was still evident that there were fewer mineralized 
traberculae in the OVX group compared to the SHAM and OVX+SIM groups (Fig. 4). In the 
cortical area, the implant surfaces were covered with mature lamella bone, and no significant 
differences were noted between the three groups (data not shown) (Du et al. 2009).  
 
Analysis of biochemical markers  
 
The serum concentrations of ALP, BALP and BGP at both 28 and 84 days are shown in figure 
6a-c. These measurements are related to the histomorphometric analysis of osseointegration 
in figure 6d.  
 
ALP levels 
The serum level of ALP at day 28 and day 84 are shown in figure 6a. At 28 days, the OVX 
group had significantly (p<0.05), higher levels of serum ALP (81.25±16.51 U/L) than the 
SHAM group (63.25±13.42 U/L), but there were no significant differences at 84 days 
between the three groups. All three groups showed higher serum ALP levels at day 84 
compared with day 28 (SHAM: 92.63±10.89 U/L VS 63.25±13.42 U/L, p<0.05; OVX: 
101.50±13.52 U/L VS 81.25±16.51 U/L, p<0.01; OVX+SIM: 93.88±16.21 U/L VS 
69.25±13.99 U/L, p<0.01).  
 
BALP levels 
The BALP levels at day 28 and day 84 are shown in Figure 6b. At 28 days, the serum level of 
BALP in the OVX+SIM group (3.73±0.46ng/ml) was significantly higher than both the OVX 
(2.97±0.55ng/ml p<0.05) and SHAM (2.84±0.75ng/ml p<0.01) groups. At day 84, the serum 
BALP level in the OVX+SIM group (2.22±0.28ng/ml) was significantly higher than the OVX 
(1.50±0.34ng/ml p>0.01), but not the SHAM group (2.33±0.77ng/ml). However, at day 84, 
the SHAM group serum BALP level was significantly higher than the OVX group (p<0.01). 
Compared to day 28, the BALP level in all three groups showed a statistically significant 
decrease at day 84 (SHAM, p<0.05; OVX, p<0.01; OVX+SIM, p<0.01).  
 
BGP levels 
The BGP levels at day 28 and day 84 are shown in Figure 6c. At day 28 there were no 
statistically significant differences in the level of BGP amongst all three groups (SHAM, 
4.43±0.52µmol/l; OVX, 4.99±0.64µmol/l; OVX+SIM, 4.80±0.96µmol/l). However, by day 
84, the OVX+SIM group had significantly (p<0.01) higher serum BGP levels 
(9.24±1.98µmol/l) than both the OVX (4.02±0.72µmol/l) and SHAM groups (5.05±0.76 
µmol/l).  No statistically significant differences were noted between the OVX and SHAM 
group. Compared with day 28, there was a statistically significant (p<0.01) increase in the 
serum BGP levels in the OVX+SIM group at day 84, but not the SHAM and OVX groups 
(Fig 6c). 
  
Summary of histomorphometric analysis 
A summary of a previous quantitative analysis of bone to implant contact (BIC) around the 
implants at days 28 and 84 (Du et al. 2009) is shown in figure 6d for the purpose of 
comparison to the serum bone marker levels.  The results showed that the BIC was higher in 
the SHAM and OVX+SIM groups compared with the OVX group at both 28 (p<0.05) and 84 
days (p<0.01).  There were no statistically significant differences in BIC between the SHAM 
and OVX+SIM groups at either 28 or 84 days after implantation. All three groups showed 
greater BIC at 84 days compared with 28 days (p<0.001). 
 
Discussion 
Simvastatin is a HMG-CoA reductase inhibitor which inhibits cholesterol biosynthesis and is 
widely used as a cholesterol-lowering drug. Recently, it has been reported that the liposoluble 
statin, Simvastatin, could increase the expression of BMP-2 mRNA in osteoblasts and, as a 
result, promote bone formation (Mundy et al. 1999). The anabolic effect of statins on bone 
metabolism has been further reported in a number of animal studies (Oxlund et al. 2001, 
Skoglund et al. 2002). This phenomenon has generated great interest amongst researchers to 
investigate potential applications of statins in the treatment of bone-related diseases, as well 
as in oral implantology. A limited number of studies have reported the effects of statins on the 
osseointegration of dental implants (Ayukawa 2004, Ayukawa et al. 2010), and we have 
previously shown that simvastatin can counter the compromised nature of osseointegration 
that is characteristic of osteoporosis (Du et al. 2009). However, the biological mechanisms 
for this effect are unknown.  Given that serum levels of bone proteins (BALP, BGP) are 
utilized for osteoporotic status assessment and evaluation of osteoporosis treatment outcomes 
(Biver et al. 2011, Pagani et al. 2005), we sought to correlate the serum levels of these 
markers with our histological assessment of osseointegration in simvaststin treated 
osteoporotic rats.  
Total serum ALP, and more specifically, the serum activity of the bone-specific isoenzyme of 
BALP and serum bone gamma-carboxyglutamic acid-containing protein BGP or osteocalcin 
(OC) are widely accepted bone formation markers (Biver et al. 2011, Pagani et al. 2005). The 
total ALP level in serum is less sensitive and specific as a bone formation marker due to the 
contribution of alkaline phosphates from non-skeletal sources. Meanwhile, BALP, which is 
produced by immature osteoblasts, plays an essential role in the initiation of bone 
mineralization and is a more specific marker of bone formation (Whyte 1994). Evaluation of 
the serum concentration of these markers and correlation with a histological assessment of 
osseointegration would provide important information about the biological mechanisms 
associated with the influence of simvastatin treatment on bone healing in osteoporotic 
patients. 
 
In this study, it was noted that after 28 days, the OVX group had higher ALP levels compared 
with SHAM group. This phenomenon might indicate that the OVX group had a higher 
proportion of bone turnover, in terms of bone resorption and bone formation. In the 
OVX+SIM group, the level of ALP was no different compared to the SHAM group. This 
implies that simvastatin might partly reverse the high turnover characteristic of osteoporosis 
through the enhancement of osteoblast activity and differentiation and reduced osteoclastic 
activity. The level of BALP in the OVX+SIM group was higher compared with the OVX and 
SHAM groups at day 28, which further confirmed that simvastatin could promote bone 
formation through enhanced osteoblast activity.  
 The BALP serum level results correlated with both qualitative and quantitative (BIC%) 
histological analysis. At day 28, the BIC of titanium implants in both the OVX+SIM and 
SHAM groups was significantly higher compared with the OVX group, suggesting that 
simvastatin promotes bone formation around titanium implant during the early stages of 
osseointegration. Simvastatin treatment resulted in more bone cells around the implants 
compared with the untreated OVX group, while displaying similar bone healing 
characteristics to the SHAM group. The results of the BALP serum levels analysis suggests 
that this may be through increased levels of osteoblastic activity in response to the application 
of simvastatin. BALP is a sensitive bone formation marker during early osteogenesis. BALP 
functions as an ectoenzyme and is attached to the osteoblast cell membrane (Magnusson et al. 
1997). It has been suggested that BALP could act as a plasma membrane transporter for 
inorganic phosphate, or an extracellular calcium-binding protein that stimulates calcium 
phosphate precipitation and orients mineral deposition into osteoid (Debernard et al. 1986). 
BALP may also be involved in the mineralization process by hydrolyzing organic phosphates 
to release free inorganic phosphate at sites of mineralization.  
At day 84, serum levels of both BGP and BALP in the OVX+SIM group were higher than 
OVX group. The serum levels of BGP in the OVX+SIM group was also higher than the 
SHAM group. These results indicate that simvastatin continued to promote osteoblastic 
activity as the newly formed bone around the implant matured, and is consistent with 
histological observations of increased bone formation and BIC in the OVX+SIM compared to 
the OVX group. 
Interestingly, the serum levels of BALP and BGP showed divergent trends in expression 
between days 28 and 84, with BALP decreasing and BGP increasing over time. The relatively 
weak correlation between these two markers may reflect the expression of these proteins at 
different stages of osteoblast differentiation (Mora et al. 1999). It is known that BGP and 
BALP are produced exclusively by osteoblasts but at different developmental stages. BALP is 
secreted by immature osteoblasts and BGP is produced by mature osteoblasts (Wang et al. 
2006). BALP activity has been reported to be necessary for the initiation of mineralization 
but not for the continuation of the process (Hooper 1997). Indeed, reports indicating that 
statins promote osteocalcin expression by inhibiting the Rho and Rho-kinase pathway 
(Ohnaka et al. 2001) provide insights into the possible biological mechanism responsible for 
the increased serum levels of BGP in the OVX+SIM group. The levels of total ALP showed 
no significant differences between the three groups at 84 days, indicating that total ALP is not 
a reliable marker of enhanced bone formation in osteoporotic animals treated with 
simvastatin. The comparison of serum BALP and BGP levels with the extent of bone 
formation around dental implants showed that both of these proteins could be positively 
correlated with the enhanced osseointegration induced by simvastatin treatment of 
osteoporotic rats, with BALP associated with early bone formation and BGP with the later 
stages of osseointegration.  
In conclusion, the present study demonstrated that serum level of biomarkers of bone 
formation, namely BALP and BGP, are correlated with osteointegration in osteoporotic and 
simvastatin treated rats.   
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Legends 
Figure 1. X-ray image of the implant position within the rat tibia 
Figure 2.  Timeline of the experimental design. 
Figure 3.  Histological evaluation (methylene blue-basic fuchsin staining) of bone changes 
around implants at days 28 and 84. Compared with day 28, there was more new bone formed 
around the implants at 84 day in each group. At both timepoints, the OVX (b and e) group 
showed thinner and discontinuous osseointegration on the surface of implants compared with 
the SHAM (a and d) and OVX+SIM (c and f) groups. (bar=200μm) 
Figure 4. Toluidine Blue staining of bone tissue in direct contact with implant surface. Bone 
matrix (yellow arrows) and bone cells (red arrows) are evident adjacent to the implant surface 
at both timepoints. Compared with day 28, the bone tissue around the implants became more 
mature in all three groups at day 84.  At both days 28 and 84, the bone tissue in the 
OVX+SIM ( c and f ) group had more bone matrix and cells than the OVX ( b and e ) group, 
but similar bone volume to the SHAM (a and d) group. At day 28, a thick immature bone 
matrix was evident in the OVX+SIM group (c). (Bar=20μm). 
Figure 5. Distribution of osteoclasts (yellow arrow) and osteoblasts (black arrow) during 
osseointegration in the ovariectomized rat (OVX) at day 28 (a) and day 84 (b) (Bar=50μm). 
Figure 6. Concentration (mean±95% CI) of (a) serum total ALP, (b) serum BALP and (c) 
serum BGP in the three experimental groups at days 28 and 84. (d) Bone to implant contact 
(BIC, mean±95% CI) around the implants for the different experimental groups at days 28 
and 84. Asterisks denote statistically significant differences between groups (* p<0.05, 
**p<0.01). 
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